Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
$44.40-0.20%
报价 2026-11-06
市值
$3.97B
EV
$4.09B
PE (TTM)
30.2x
预期 PE (FY2026)
21.9x
52 周区间距高点 -51.2%
$25.91$91.03
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LQDALiquidia Corporation | $3.97B | -0.2% | +371.0% | 92.5% | 30.2x | 23.0x | 70.1x | |
| IBRXImmunityBio, Inc. | $9.15B | +7.8% | +92.7% | 94.6% | – | – | – | |
| COGTCogent Biosciences, Inc. | $5.49B | +7.0% | +646.7% | 0% | – | – | – | |
| DNLIDenali Therapeutics Inc. | $3.21B | +1.8% | +1848.0% | 0% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.59B | +3.3% | -70.3% | 97% | – | – | – | |
| MESOMesoblast Limited | $1.85B | +1.2% | – | 78.3% | – | – | – | |
| AGIOAgios Pharmaceuticals, Inc. | $1.76B | +4.0% | +160.7% | 87.9% | – | – | – | |
| OCULOcular Therapeutix, Inc. | $1.45B | +2.6% | -5.3% | 87.4% | – | – | – | |
| GPCRStructure Therapeutics Inc. | $1.17B | +6.7% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +126.7% | 82.8% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。